目次

Table of Contents

List of Tables

List of Figures
Introduction
Global Markets Direct Report Coverage
Fibromyalgia (Fibromyalgia Syndrome) - Overview
Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development
Aardvark Therapeutics Inc
Aptinyx Inc
Cortene Inc
Engrail Therapeutics Inc
Epitech Group SpA
H. Lundbeck AS
Imbrium Therapeutics LP
Indaptus Therapeutics Inc
Luye Pharma Group Ltd
One World Cannabis Ltd
PRISM Pharma Co Ltd
Reven Holdings Inc
Shanghai Lvdao Pharmaceutical Technology Co Ltd
Statera Biopharma Inc
Tetra Bio-Pharma Inc
Teva Pharmaceutical Industries Ltd
Tonix Pharmaceuticals Holding Corp
Tryp Therapeutics Inc
Virios Therapeutics, Inc
Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
History of Events
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
CT-38 - Drug Profile
Product Description
Mechanism Of Action
dronabinol - Drug Profile
Product Description
Mechanism Of Action
History of Events
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
LD-04185 - Drug Profile
Product Description
Mechanism Of Action
LuAG-06466 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-03012 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MS-11 - Drug Profile
Product Description
Mechanism Of Action
naltrexone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
NP-013 - Drug Profile
Product Description
Mechanism Of Action
NYX-2925 - Drug Profile
Product Description
Mechanism Of Action
History of Events
palmidrol - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
PPP-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
psilocybin - Drug Profile
Product Description
Mechanism Of Action
RPOT-1002a - Drug Profile
Product Description
Mechanism Of Action
Small Molecule 1 to Agonize CB1 and CB2 for Chronic Pain and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize CB1 and CB2 for Fibromyalgia and Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
History of Events
sunobinop tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
TNX-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRP-8803 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Type 1 Diabetes and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects
Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products
Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones
Featured News & Press Releases
Feb 09, 2022: Aptinyx hosts virtual portfolio review event to showcase NYX-2925 in chronic pain
Dec 03, 2021: Tryp Therapeutics to present at the H.C. Wainwright Psychedelics Conference on December 6, 2021
Dec 02, 2021: Tryp Therapeutics receives confirmation from FDA to proceed with phase 2a study in fibromyalgia
Dec 01, 2021: Virios Therapeutics achieves over 50% enrollment milestone in its phase 2b clinical trial for fibromyalgia
Nov 08, 2021: Tonix Pharmaceuticals presents positive results from phase 3 relief study of TNX-102 SL for the management of fibromyalgia at the American College of Rheumatology Convergence 2021
Sep 27, 2021: Tonix Pharmaceuticals announces oral presentation at the American College of Rheumatology Convergence 2021
Aug 16, 2021: Virios Therapeutics CEO highlights novel therapeutic approach for treating fibromyalgia and irritable bowel syndrome in Stock News now video interview
Jul 26, 2021: Virios Therapeutics highlights clinical sites fully operational in phase 2b fibromyalgia study featuring FDA "Fast Track" review designated antiviral therapy, oral IMC-1
Jun 09, 2021: Virios Therapeutics highlights safety data from phase 2a fibromyalgia trial at the International Association for the Study of Pain (IASP) World Congress
Jun 04, 2021: Virios Therapeutics announces dosing of first patient in phase 2b trial evaluating IMC-1 in patients with fibromyalgia
Jun 03, 2021: Tonix Pharmaceuticals presents positive results from phase 3 relief study of TNX-102 SL for the management of fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Jun 02, 2021: Virios Therapeutics presents phase 2a Fibromyalgia trial data on efficacy analyses of key secondary endpoints at the EULAR European Congress of Rheumatology
May 26, 2021: Tonix Pharmaceuticals announces presentation of two posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 24, 2021: Virios Therapeutics announces oral presentation of clinical data at Digestive Disease Week (DDW)
May 10, 2021: Tryp Therapeutics partners with Clinlogix for clinical trial support
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aardvark Therapeutics Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aptinyx Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Cortene Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Engrail Therapeutics Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Epitech Group SpA, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by H. Lundbeck AS, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Imbrium Therapeutics LP, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Indaptus Therapeutics Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Luye Pharma Group Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by One World Cannabis Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by PRISM Pharma Co Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Reven Holdings Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Shanghai Lvdao Pharmaceutical Technology Co Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Statera Biopharma Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tetra Bio-Pharma Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tryp Therapeutics Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Virios Therapeutics, Inc, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022 (Contd..1)
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, 2022 (Contd..2)
Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022